BTIG Research Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs (NASDAQ:ESTA) had its price target increased by stock analysts at BTIG Research from $86.00 to $88.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s target price would suggest a potential upside of 12.40% from the stock’s previous close.

A number of other equities research analysts have also weighed in on the stock. Canaccord Genuity Group boosted their target price on shares of Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Needham & Company LLC upped their price objective on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday. Citigroup increased their target price on Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. boosted their price target on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Finally, Mizuho upped their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $86.29.

Establishment Labs Price Performance

ESTA opened at $78.29 on Tuesday. The company’s 50-day simple moving average is $71.06 and its two-hundred day simple moving average is $57.87. The company has a debt-to-equity ratio of 15.06, a quick ratio of 2.10 and a current ratio of 3.33. The stock has a market capitalization of $2.28 billion, a P/E ratio of -44.99 and a beta of 0.99. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The firm had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 197.22%. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the business posted ($1.19) earnings per share. As a group, analysts predict that Establishment Labs will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

Several hedge funds have recently bought and sold shares of ESTA. MV Capital Management Inc. bought a new position in shares of Establishment Labs during the 4th quarter valued at about $146,000. ADAR1 Capital Management LLC lifted its position in shares of Establishment Labs by 89.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 171,422 shares of the company’s stock worth $12,493,000 after buying an additional 80,734 shares in the last quarter. Voloridge Investment Management LLC purchased a new stake in shares of Establishment Labs in the fourth quarter worth about $3,421,000. SummitTX Capital L.P. bought a new position in Establishment Labs during the fourth quarter valued at approximately $2,519,000. Finally, Tudor Investment Corp ET AL purchased a new position in Establishment Labs during the 4th quarter valued at approximately $12,852,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

More Establishment Labs News

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 results beat expectations — EST A reported EPS of ($0.09) vs. a ($0.22) consensus and revenue of $64.62M (+45% y/y). Revenue beat and margin improvement were driver-positive for sentiment. Press Release
• Positive Sentiment: 2026 revenue guidance raised — Company provided FY2026 revenue guidance of $264.0M–$266.0M and is targeting at least 25% revenue growth, signaling continued top-line momentum. MSN Article
• Positive Sentiment: Multiple analyst upgrades/price-target raises — Stephens ($85→$90, overweight), Mizuho ($90→$100, outperform), BTIG ($86→$88, buy) and Needham ($84→$86, buy) boosted targets, reflecting bullish analyst views on growth trajectory. Benzinga Analyst Rundown
• Neutral Sentiment: Leadership transition announced — Company disclosed a leadership change intended to support the next growth phase; could be positive if execution steadies but creates short-term uncertainty. Yahoo Finance
• Neutral Sentiment: Full earnings materials and call transcript available — Analysts and investors can review details and management commentary to assess margin trajectory and M&A/R&D plans. Earnings Call Transcript
• Negative Sentiment: Company remains unprofitable — EST A reported a negative net margin (~-43%) and negative ROE; consensus still models negative EPS for the fiscal year, highlighting path to consistent profitability is not yet clear. Zacks
• Negative Sentiment: Short-term selling pressure despite positives — intraday volume has spiked above average while the stock trades down, suggesting some investors are booking gains or reacting to remaining execution/earnings risk. Benzinga

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.